Interpace Biosciences: Vijay Aggarwal
Interpace Biosciences has appointed Vijay Aggarwal to its board of directors, effective Feb. 1. Aggarwal is currently managing partner of life sciences strategic advisory company The Channel Group. He previously served as CEO of Vaxigenix, a pharmaceutical company developing treatments for colorectal cancer. He was also president and CEO of predictive pathology company Aureon Laboratories, which offered advanced tissue analysis services to physicians and the pharma industry. Aggarwal also served as president of Quest Diagnostics Ventures, where he was responsible for new technology, new business models, clinical trials testing, and direct-to-consumer strategies. He also held a variety of positions earlier in his career at SmithKline Beecham Clinical Laboratories, including EVP of laboratories and VP of managed care.